Abatacept in difficult-to-treat juvenile idiopathic arthritis

Jasmin B Kuemmerle-Deschner1, SM Benseler21Pediatric Rheumatology Clinics, Dept of Pediatrics, University Hospital T&uuml;bingen, Germany; 2Dept of Pediatric Rheumatology, The Hospital for Sick Children, Toronto, CanadaAbstract: Juvenile idiopathic arthritis (JIA) is the most common chronic...

Descripción completa

Guardado en:

Detalles Bibliográficos
Autores principales:	Jasmin B Kuemmerle-Deschner, SM Benseler
Formato:	article
Lenguaje:	EN
Publicado:	Dove Medical Press 2009
Materias:	Medicine (General) R5-920
Acceso en línea:	https://doaj.org/article/75fa9ca6eb904d318c615cc567d7e322
Etiquetas:	Agregar Etiqueta Sin Etiquetas, Sea el primero en etiquetar este registro!

id	oai:doaj.org-article:75fa9ca6eb904d318c615cc567d7e322
record_format	dspace
spelling	oai:doaj.org-article:75fa9ca6eb904d318c615cc567d7e3222021-12-02T04:28:56ZAbatacept in difficult-to-treat juvenile idiopathic arthritis1177-54751177-5491https://doaj.org/article/75fa9ca6eb904d318c615cc567d7e3222009-02-01T00:00:00Zhttp://www.dovepress.com/abatacept-in-difficult-to-treat-juvenile-idiopathic-arthritis-a2832https://doaj.org/toc/1177-5475https://doaj.org/toc/1177-5491Jasmin B Kuemmerle-Deschner1, SM Benseler21Pediatric Rheumatology Clinics, Dept of Pediatrics, University Hospital T&uuml;bingen, Germany; 2Dept of Pediatric Rheumatology, The Hospital for Sick Children, Toronto, CanadaAbstract: Juvenile idiopathic arthritis (JIA) is the most common chronic rheumatic disease in children and an important cause of short-term and long-term disability. Gene changes in the immune system can predispose to JIA and regulation of the immune system is crucial in the pathogenesis. The goal of therapy is complete disease control using disease-modifying antirheumatic drugs (DMARDS). Activated T-cells may play a role in the immunopathology of JIA. Therefore, targeting T-cell activation is a rational approach for the treatment of JIA. Abatacept (ABA), a selective co-stimulation modulator, has been shown to be effective in treating all JIA subtypes and is generally safe and well tolerated in JIA. Neutralizing antibodies were found in 6/9 (67%) of seropositive patients, but anti-ABA antibodies did not appear to be associated with disease flare, serious adverse events, acute infusional adverse events, hypersensitivity, autoimmune disorders, or low ABA serum concentrations. Anti-ABA antibodies were more frequent when ABA concentrations were below therapeutic levels. Although information on ABA in JIA is still limited, available data suggest a potential role in difficult to treat JIA patients previously treated with other biologic agents and for non-responders to TNF-blockade.Keywords: abatacept, juvenile idiopathic arthritis (JIA), biologics Jasmin B Kuemmerle-DeschnerSM BenselerDove Medical PressarticleMedicine (General)R5-920ENBiologics: Targets & Therapy, Vol 2008, Iss Issue 4, Pp 865-874 (2009)
institution	DOAJ
collection	DOAJ
language	EN
topic	Medicine (General) R5-920
spellingShingle	Medicine (General) R5-920 Jasmin B Kuemmerle-Deschner SM Benseler Abatacept in difficult-to-treat juvenile idiopathic arthritis
description	Jasmin B Kuemmerle-Deschner1, SM Benseler21Pediatric Rheumatology Clinics, Dept of Pediatrics, University Hospital T&uuml;bingen, Germany; 2Dept of Pediatric Rheumatology, The Hospital for Sick Children, Toronto, CanadaAbstract: Juvenile idiopathic arthritis (JIA) is the most common chronic rheumatic disease in children and an important cause of short-term and long-term disability. Gene changes in the immune system can predispose to JIA and regulation of the immune system is crucial in the pathogenesis. The goal of therapy is complete disease control using disease-modifying antirheumatic drugs (DMARDS). Activated T-cells may play a role in the immunopathology of JIA. Therefore, targeting T-cell activation is a rational approach for the treatment of JIA. Abatacept (ABA), a selective co-stimulation modulator, has been shown to be effective in treating all JIA subtypes and is generally safe and well tolerated in JIA. Neutralizing antibodies were found in 6/9 (67%) of seropositive patients, but anti-ABA antibodies did not appear to be associated with disease flare, serious adverse events, acute infusional adverse events, hypersensitivity, autoimmune disorders, or low ABA serum concentrations. Anti-ABA antibodies were more frequent when ABA concentrations were below therapeutic levels. Although information on ABA in JIA is still limited, available data suggest a potential role in difficult to treat JIA patients previously treated with other biologic agents and for non-responders to TNF-blockade.Keywords: abatacept, juvenile idiopathic arthritis (JIA), biologics
format	article
author	Jasmin B Kuemmerle-Deschner SM Benseler
author_facet	Jasmin B Kuemmerle-Deschner SM Benseler
author_sort	Jasmin B Kuemmerle-Deschner
title	Abatacept in difficult-to-treat juvenile idiopathic arthritis
title_short	Abatacept in difficult-to-treat juvenile idiopathic arthritis
title_full	Abatacept in difficult-to-treat juvenile idiopathic arthritis
title_fullStr	Abatacept in difficult-to-treat juvenile idiopathic arthritis
title_full_unstemmed	Abatacept in difficult-to-treat juvenile idiopathic arthritis
title_sort	abatacept in difficult-to-treat juvenile idiopathic arthritis
publisher	Dove Medical Press
publishDate	2009
url	https://doaj.org/article/75fa9ca6eb904d318c615cc567d7e322
work_keys_str_mv	AT jasminbkuemmerledeschner abataceptindifficulttotreatjuvenileidiopathicarthritis AT smbenseler abataceptindifficulttotreatjuvenileidiopathicarthritis
_version_	1718401192744189952

Abatacept in difficult-to-treat juvenile idiopathic arthritis

Ejemplares similares